Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002985 · ClinicalTrials.gov registry record · Phase 3

Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma

A Phase 3 study of Sarcoma, sponsored by Roswell Park Cancer Institute.

Completed
Registry status
Phase 3
Development phase
1
Study location

NCT00002985 is a Phase 3 study of Sarcoma that has completed, run by Roswell Park Cancer Institute. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002985, a Phase 3 study of Sarcoma, has completed, sponsored by Roswell Park Cancer Institute.

COMPLETED
Registry status
Phase 3
Development phase
1
Study location

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether doxorubicin is more effective than daunorubicin for AIDS-related Kaposi's sarcoma. PURPOSE: Randomized double-blinded phase III trial to determine if doxorubicin is more effective than daunorubicin in treating patients who have AIDS-related Kaposi's sarcoma.

Conditions Studied

Interventions

  • DRUG pegylated liposomal doxorubicin hydrochloride
  • DRUG daunorubicin hydrochloride

Study Locations (1)

New York

  • Roswell Park Cancer Institute - Buffalo

Trial Details

FieldValue
Start Date 1996-11
Phase Phase 3

Sponsor

Roswell Park Cancer Institute

365 total trials

What the Registry Record Tells You About NCT00002985

The ClinicalTrials.gov registry entry for NCT00002985 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which pegylated liposomal doxorubicin hydrochloride is the first listed.

NCT00002985 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00002985 about?

NCT00002985 is a clinical study titled "Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether doxorubicin is more effective than daunorubicin for AIDS-related Kaposi's sarcoma. PURPOSE: Randomized double-blinded phase III trial to determine if d...

What is the current status of trial NCT00002985?

This trial is currently completed. It is a Phase 3 study. The study started on 1996-11.

What conditions does trial NCT00002985 study?

This clinical trial studies the following conditions: Sarcoma.

What interventions are being tested in trial NCT00002985?

The interventions under investigation include: pegylated liposomal doxorubicin hydrochloride (DRUG), daunorubicin hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00002985?

This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002985 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.